&w=3840&q=100)
2 smallcaps zoom up to 153% from April low. What's driving these stocks?
Shares of Suven Life Sciences (Suven) and Camlin Fine Sciences (CFSL) hit their respective new highs, surging up to 9 per cent on the BSE in Monday's intra-day trade. The stock price of both these smallcap companies have outperformed the market, by zooming up to 153 per cent from their April month lows. On April 7, 2025, the market including BSE Sensex, BSE Midcap and BSE Smallcap indices recorded their respective 52-week lows.
Individually, Suven has rallied 9 per cent to ₹257.70 in intra-day trade today. In the past one month, the market price of the healthcare research, analytics & technology company has surged 36 per cent. It has bounced back 124 per cent from its April 7, 2025 low of ₹115 on the BSE.
Shares of Camlin soared 7 per cent to ₹324.20, surging 67 per cent in the past one month. The stock price of this specialty chemicals makee has zoomed 153 per cent from a level of ₹128.10 touched on April 7, 2025.
What's driving Suven, Camlin stock prices?
CFLS reported a strong operational performance for the March 2025 quarter (Q4FY25). The company reported 88.7 per cent year-on-year (YoY) growth in earnings before interest, taxes, depreciation and amortisation (EBITDA) from its continuing operations at ₹59.41 crore, as against ₹31.48 crore in Q4FY24. Reported EBITDA margins expanded to 13.6 per cent from 8.4 per cent from the year ago quarter. Revenue from operations grew 16.1 per cent YoY to ₹437.46 crore from ₹376.65 crore. Profit after tax (PAT) increased 16.9 per cent YoY at ₹22.74 crore.
At the consolidated level, CFSL derives around 85 per cent of its revenue from exports and from overseas subsidiaries, with over 100 products sold in around 80 countries. The company caters to diverse end user industries such as food, feed, animal and pet nutrition, flavours and fragrances, pharma, agrochemicals, and petrochemicals among others. This helps the company avoid dependence on any single industry and provides potential for expansion.
Management anticipates sustained momentum in this segment, projecting a compounded annual growth rate (CAGR) of ~20 per cent over the next 2–3 years. Margins are expected to expand further as the bleeding from continued operations reduces and other operations grow. Camlin is also set to benefit from the implementation of anti-dumping measures in the US and improving Vanillin prices. While steady performance improvement is expected, the analysts remain cautious of near-term uncertainties related to tariffs and capacity ramp-up.
Suven, a bio-pharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.
On May 13, the board of directors of Suven approved fund raising of ₹857.64 crore through fully convertible warrants on preferential basis to continue the funding of R&D, Clinical Development programs and general corporate purposes and CAPEX for creating new R&D facilities.
Suven has a significant opportunity in the rapidly growing CNS segment. The segment has limited competition due to high associated risks. CNS diseases include a broad spectrum of disorders in which the brain or spinal cord functioning is diminished or impaired, resulting in diminished motor, sensory, or cognitive performance.
The rising prevalence of CNS disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis and depression, drives the demand for effective CNS therapeutics. Furthermore, the pandemic has resulted in increased stress levels, anxiety, depression and other mental conditions. This has led to an increased demand for CNS therapies.
Suven continues its R&D programs focused on CNS disease disorders and has secured 20 patents during the period covering countries Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa and the US.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
27 minutes ago
- Mint
Pharma stock under ₹50 jumps 4% after Q1 results 2025 and business updates
Stock Market Today: Pharma stock under ₹ 50 gained more than 3% during intraday trades on Monday after Q1 results for 2025 were announced on Friday after market hours and business updates pertaining to an acquisition. Check details about Sudarshan Pharma Industries Limited Sudarshan Pharma Industries, during the quarter ending June 2025, reported a net profit of ₹ 3.74 crore compared to a loss of ₹ 1.18 crore in the year ago quarter. On the sequential basis the net profit declined from ₹ 7.03 crore during the January-March 2025 quarter; however, the previous quarter had seen exceptional gains of ₹ 1.65 crore. The revenue from operations at ₹ 142.31 crore during Q1FY26, however, jumped close to 40% compared to ₹ 101.73 crore in Q1FY25. On the sequential basis the revenues, however, dipped slightly compared to . ₹ 161.57 crore in the January-March 2025 quarter. Sudarshan Pharma Industries, in addition to Q1 financial results, also announced the acquisition updates. The Sudarshan Pharma Industries said that the company shall acquire land, buildings, plant & machinery assets, and an area totaling approximately 1563.15 square meters. located in the state of Telangana, from Srigen Lifesciences Private Limited. The total sale consideration as per Sudarshan Pharma is ₹ 25.50 crore. It has developed 50 potential API key starting materials having viable commercial technology. A few key starting materials were held as patent rights by Srigen Lifesciences Private Limited and are currently being manufactured on a commercial scale with proper regulatory documentation support. The plant has 80-kiloliter reactor capacity in its manufacturing facility. The acquisition will lead to strengthening production capacities of Sudarshan Pharma Industries. Sudarshan Pharma Industries' share price opened at ₹ 31.50 , on the BSE on Monday. At the time of opening, the Sudarshan Pharma Industries share price was more than 1% higher compared to the previous trading session's closing price of ₹ 31.06. The Sudarshan Pharma Industries share price thereafter rose to intraday highs of ₹ 32.50, which meant gains of more than 4% during the intraday trades. Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
an hour ago
- Mint
Ashish Kacholia portfolio stock jumps 11% on Q1 results 2025. Details here
Shares of Zaggle Prepaid Ocean Services surged over 11% on Monday's session after strong Q1 results. On Thursday, August 14, the Fintech company announced that its consolidated net profit surged by 56% year-on-year, reaching approximately ₹ 26 crore for the first quarter that ended in June 2025. This marks an increase from the net profit of ₹ 16.73 crore recorded in the same quarter last year, according to a regulatory filing by Zaggle Prepaid Ocean. Zaggle Prepaid Ocean's operational revenue rose by around 32% to ₹ 332 crore for the reported quarter, compared to ₹ 252.2 crore in the quarter ending June 2024. "Our first-quarter performance has been our strongest to date, even though it is typically a slower period in the year. The growth in our total customer base and user numbers has led to noticeable healthy growth across our revenue streams," stated Raj P Narayanam, Founder and Executive Chairman of Zaggle Prepaid Ocean Services. The firm has recently welcomed clients including Hindustan Pencils, Apollo Health, Mo Engage, Novozymes, DTDC, CK Birla Healthcare, and Truecaller. Narayanam mentioned that the company is achieving new heights of scale and efficiency by placing AI at the center of its product strategy. Ashish Kacholia holds a 2.24% stake in Zaggle Prepaid Ocean Services, which is equivalent to 3,003,356 shares. Zaggle Prepaid share price today opened at ₹ 387 apiece on the BSE, the stock touched an intraday high of ₹ 409.50 per share and an intraday low of ₹ 383.25 apiece. Rajesh Bhosale, Equity Technical and Derivative Analyst at Angel One, explained that on the daily chart, we are seeing a bullish reversal Kicking candlestick pattern, the formation is seen with strong surge in volumes and has helped prices to confirm a range breakout. Prices are likely to extend upmove possibly towards 430 levels in the near term, whereas 380 followed by 360 is seen as strong support. Disclaimer: The views and recommendations above are those of individual analysts, experts and broking companies, not of Mint. We advise investors to check with certified experts before making any investment decision.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Bajaj Finance spurts 7% after S&P Global Ratings upgrade; details here
Share price of Bajaj Finance today Shares of Bajaj Finance surged 7 per cent to ₹919.15 on the BSE in Monday's intra-day trade amid heavy volumes after ratings agency - S&P Global Ratings upgraded the company's credit rating from BBB-/Positive/A-3 to BBB/Stable/A-2. S&P Global Ratings upgraded ratings of 7 banks and 3 NBFCs to 'BBB' This credit rating upgrade is linked to revision in India's sovereign credit rating. Though such rating upgrade is seen to aid growth and attract capital, near term benefit on valuation remains limited. Bajaj Finance's creditworthiness benefits from the company's strong market position in the financing of consumer durables and two- and three-wheelers, and its adequate liquidity, S&P Global Ratings said in its rationale. The rating agency expects Bajaj Finance to sustain its RAC ratio above 15 per cent, in line with a very strong capital and earnings assessment over the next 12-24 months. The ratio was 18.9 per cent as of March 31, 2025, benefiting from lower risk weights because risks are recalibrated to reflect India's improved economic environment and the upgrade of the sovereign. The rating agency also expects the ratio to benefit from the company's good profitability and low dividend payout amid some pressure from the company's likely above-average loan growth. 'The stable rating outlook reflects our view that Bajaj Finance will maintain its strong market position and healthy capital position over the next two years. We also expect the company's liquidity and funding profile to remain adequate over the period. A downgrade of Bajaj Finance is unlikely over the next 12-24 months, in our view,' S&P Global Ratings said. GST rationalization As per media reports, the Finance Ministry has proposed a simplified two-slab system for Goods and Service Tax (GST) for most products vs existing 4-tier structure of 5 per cent, 12 per cent, 18 per cent and 28 per cent. Prime Minister Narendra Modi in his Independence Day speech stated the next generation GST reforms will be a Diwali gift for the country. Reports suggest the rates could be reduced to 18 per cent and 5 per cent. The move, if implemented, is expected to lower prices by ~10 per cent, thereby boosting affordability and penetration, particularly in energy-efficient ACs which have low penetration. With sentiment already subdued due to weak summer demand and high inventory levels, the GST cut could provide timely relief and drive volume growth in the upcoming festive season. Bajaj Finance is one of India's largest and well-diversified non-banking finance companies (NBFC). The company provides loans for two wheelers, consumer durables, housing, SME & MSME businesses etc. Bajaj Finance has an asset under management (AUM) of ~₹4.41 trillion as of June 2025, and continues to be the largest consumer durables lender in India. Moody's Ratings view on Bajaj Finance Bajaj Finance's profitability is one of the highest amongst our rated Indians NBFCs because of its presence in high yielding segments, competitive borrowing costs, and strong economies of scale. Moody's Ratings in rating action dated August 4, 2025, said that it expects Bajaj Finance's profitability to benefit from a reduction in cost of funding because of policy rate cuts feeding through its borrowing rates, The Reserve Bank of India (RBI) reduced its policy rate by 100 basis points starting from February 2025. However, credit cost should remain elevated. 'We expect the company to maintain one of the lowest stage 3 loans in the industry, which stood at 1 per cent of total loans as of end June 2025 with overall provision coverage of 165 per cent. Bajaj Finance is experiencing higher delinquencies in some unsecured lending categories and small business loans mainly driven by the overleveraging of some customers. It is also winding down its 2 & 3-wheeler business and taking charge-offs in this process,' Moody's Ratings said.
